Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer

Autor: Vriens, B.E., Aarts, M.J., Vries, B. de, Gastel, S.M. van, Wals, J., Smilde, T.J., Warmerdam, L.J. van, Boer, M. de, Spronsen, D.J. van, Borm, G.F., Tjan-Heijnen, V.C., Stienen, J.J.C., Hermens, R.P.M.G., Wennekes, L., Schans, S.A. van de, Dekker, H.M., Blijlevens, N.M.A., Maazen, R.W.M. van der, Adang, E.M.M., Krieken, J.H.J.M. van, Ottevanger, P.B.

Publikováno v: European Journal of Cancer, 49, 15, pp. 3102-10
European Journal of Cancer, 49, 3102-10
European Journal of Cancer, 49(15), 3102-3110. ELSEVIER SCI LTD

Contains fulltext : 127295.pdf (Publisher’s version ) (Closed access) Abstract BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8001ddddc5bfe493a9714483c16228b6
https://pubmed.ncbi.nlm.nih.gov/23850450